Reprocell Inc.
https://www.reprocell.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reprocell Inc.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Regenerative Medicine Policy In Japan Could Serve As Global Breeding Ground For New Technologies
Japan’s evolving policy on regenerative medicine approval and safety could create a gateway for global market entry.
Regenerative Medicine Policy In Japan Could Serve As Global Breeding Ground For New Technologies
Japan’s evolving policy on regenerative medicine approval and safety could create a gateway for global market entry.
Deals Shaping The Medical Industry, September 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice